Status
Conditions
Treatments
About
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal